CD19 and acute lymphoblastic leukemia: Stanford University initiated a Phase I trial (NCT03233854) to evaluate a unique loop CD19–22 CAR in adult patients with B-cell acute lymphoblastic leukemia (B-ALL) or LBCL [19].